Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

Best, Sarah A., De Souza, David P., Kersbergen, Ariena, Policheni, Antonia N., Dayalan, Saravanan, Tull, Dedreia, Rathi, Vivek, Gray, Daniel H., Ritchie, Matthew E., McConville, Malcolm J., Sutherland, Kate D.·2018·Cell Metabolism
DOI 10.1016/j.cmet.2018.02.006

Cited by (220)

Items 201–220 of 220

  1. Identification of Immune-Related Gene Signature Model for Predicting Lung Cancer Survival and Response to Immunotherapy
    Wenrong Lin, Xiaojun Cai, YiJin Lin, Weikun Su, Guibin Weng, Lin Chen, Jianming Ding, Yibin Cai · 2024 · Oncology
  2. Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and Interferon signaling in lung cancers harboring KEAP1/STK11 mutations
    Ziying Lin, Shrestha Ashish, Lixia Huang, Shaoli Li, Yangchan Li, Yanbin Zhou, Jincui Gu · 2025 · Research Square
  3. Endolysosomal cation channel MCOLN as the novel regulator of redox homeostasis
    Yahao Gao, Lei Xu, Ying Chen · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  4. KLHL4 upregulates EGFR signaling to promote the malignant progression of oral squamous cell carcinoma
    Yingxin Zhang, Yuan Ren, Yimei Wang, Ming Liu, Fangbu Cheng, Haiyun Li, S. Sun, Xikun Zhou, Jiantang Yang, Jing Li · 2025 · Medical Oncology
  5. Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer
    Varun Jayeshkumar Shah, Oliver Hartmann, Martin Wegner, Cristian Prieto‐Garcia, Rubina S. Kazi, Viktoria von Heyl zu Herrnsheim, Amin Wanli, Igor Mačinković, Bianka Bohnacker, Koraljka Husnjak et al. · 2026 · The EMBO Journal
  6. Circulating metabolomic profile and its association with atrial fibrillation and systemic inflammation
    Udit Thakur, William A. Figgett, Devy Deliyanti, Joshua J. Hawson, Robert Anderson, David Chieng, Sarah Kummerfeld, Peter M. Kistler, Alex J. A. McLellan, G. Lee et al. · 2026 · Heart Rhythm O2
  7. Optimizing nutritional interventions in chronic liver disease: Etiology-specific strategies for enhanced clinical management
    Mohamed Mahmoud Hafez, Mark Nasseem, Imane Boukhechem, Reda ElSheikh, Ahmed Tawheed · 2026 · World Journal of Hepatology
  8. Control of antitumor immunity by the SQSTM1 dependent signaling
    Nathalie Yazbeck · 2018
  9. Populations lymphocytaires circulantes exprimant PD-1 au cours des cancers bronchiques avancés, valeur prédictive de réponse aux inhibiteurs de PD-1/PD-L1
    Boris Duchemann · 2021 · theses.fr (ABES)
  10. Sijunzi Decoction Reverses Metabolic Adaptation and Induces Ferroptosis in Cisplatin-Resistant Non–small Cell Lung Cancer: An Integrative Metabolomics–Pharmacology Analysis
    Wenjun Liu, Han-yu Dong, Liu Chun-ying, Chun Wang · 2026 · Current Medical Science
  11. Oxidized protein states define metastatic fitness in lung cancer
    Maolin Ge, Magdy Gohar, Consuelo Torrini, Yukako Suzuki, Jiang, Yuchen Huang, Benjamin Weinstein, Janice Wong, Naema Nayyar, Md Yousuf Ali et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Sinigrin as a dual modulator of oxidative stress and neuroinflammation: Targeting Nrf-2-NF-κB crosstalk in Alzheimer’s disease
    Sanchi Jain, Romanpreet Kaur, Shamsher Singh · 2025 · Neurophysiology
  13. Nrf2 signaling pathway and its molecular regulatory mechanism
    Yunfei Pan, Xiaodong Zhang, Yimin Lu, Hao Qin, Rong Chen, Handong Fan · 2026 · Journal of Zhejiang University SCIENCE B
  14. From metabolism to genome integrity: NRF2 as a key mediator of cancer therapy response
    Andrea Sarrecchia, Claudia Di Girolamo, I Taddei, Claudia Contadini, Daniela Barilà, Claudia Cirotti · 2026 · Frontiers in Cell and Developmental Biology
  15. A Glutathione Metabolism-Related Transcriptomic Signature for Prognostic Assessment and Biological Characterization of Lung Adenocarcinoma
    Zhengzuo Sheng, Siyu Chen, Su Chen · 2026 · Cancer Informatics
  16. Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations
    Qiongyu Zhang, Zhi Qin, Caijuan Guo · 2026 · MedComm – Oncology
  17. Real-World Treatment Patterns and Clinical Outcomes After First-Line Therapy in Patients with KRAS G12C-Mutant Advanced Non-Small-Cell Lung Cancer in the United States
    Kristin M. Sheffield, Tarun Puri, Kelli Thoele, Himanshu Karu, A. Mansharamani, Dipesh Uprety · 2026 · Cancers
  18. Variant-informed multimodal tissue-state modeling reveals an NRF2 stress niche and dependency axis in KEAP1/NFE2L2-altered cancer
    Mo-Wei Kong, Qiu-Ting Li, Xing-Wei Zhao, Yu Wang, Ya-Mei Luo, Yang Yu, Chun-Xiang Zhang · 2026 · Frontiers in Immunology
  19. BindingDB Entry 50010105: Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Inhibition: An Emerging Strategy in Cancer Therapy.
    BindingDB · 2021 · UC San Diego
  20. CUL3-mediated NRF2 dysregulation in TP53-driven non-small cell lung cancer: neddylation-associated structural perturbations
    Poobana Dharmalingam, Chinnappan Sudandiradoss · 2026 · Frontiers in Bioinformatics